晨光生物(300138.SZ):莎車晨光公司完成吸收合併莎車植物蛋白
格隆匯 11 月 27日丨晨光生物(300138.SZ)公佈,公司第四屆董事會第二十二次會議審議通過了《關於子公司吸收合併的議案》,為梳理公司集團管理架構,提高運營效率,公司決定使全資子公司——晨光生物科技集團莎車有限公司(“莎車晨光”)吸收合併另一家全資子公司——晨光生物科技集團莎車植物蛋白有限公司(“莎車植物蛋白”)。吸收合併完成後,莎車晨光公司存續經營,莎車植物蛋白公司將被註銷。
近日,莎車植物蛋白公司完成了工商註銷登記。2020年11月26日,莎車晨光公司完成了吸收合併工商變更登記手續,取得了莎車縣市場監督管理局核發的營業執照。
莎車晨光公司此次營業執照變更,主要是完成了吸收合併莎車植物蛋白公司,變更了註冊資本及經營範圍。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.